NMRA Q2 2025 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$54M

Net Income

-$53M

EPS (Diluted)

$-0.33

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$52M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$224M

Total Liabilities

$41M

Stockholders' Equity

$183M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$54M	-$64M	+15.3%
Net Income	-$53M	-$59M	+10.2%